Un portavoz de Novo Nordisk, cuya patente en China para Ozempic no expira hasta 2026 pero est impugnada en los tribunales, no respondi de inmediato a una solicitud de comentarios
Plus, it doesnt have all the costs for the design of injection pens, the large manufacturing facility, and distribution
Preci DP, Almeida A, Weiler AL, Franciosi MLM, Cardoso AM
Note that oral semaglutide (Rybelsus) has specific meal-timing requirements that differ from injectable forms, which we'll cover in a later section
Whether those benefits are sustained long-term, whether the safety profile holds up across larger and more diverse populations, and whether the drug-vs-biologic classification battle shapes patient access these are the questions that 2026's remaining TRIUMPH readouts will begin to answer